Pegozafermin is a long-acting, glycopegylated FGF21 analog developed for the treatment of nonalcoholic steatohepatitis and hypertriglyceridemia. From Wikipedia
The bid centers on Phase 3 FGF21 analog pegozafermin to strengthen Roche’s cardiometabolic franchise.
